cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mind Medicine Mindmed Inc
47 own
76 watching
Current Price
$3.44
$0.03
(0.88%)
logo-mnmd
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
129.14M
52-Week High
52-Week High
22.2
52-Week Low
52-Week Low
2.12
Average Volume
Average Volume
0.46M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization129.14M
icon52-Week High22.2
icon52-Week Low2.12
iconAverage Volume0.46M
iconDividend Yield--
iconP/E Ratio--
What does the Mind Medicine Mindmed Inc do?
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Read More
How much money does Mind Medicine Mindmed Inc make?
News & Events about Mind Medicine Mindmed Inc.
PR Newswire
21days ago
MindMed Provides Corporate Update and 2023 Outlook MindMed Provides Corporate Update and 2023 Outlook PR Newswire NEW YORK, Jan. 9, 2023 - Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 - Company to initiate first clinical trial...
CNW Group - News Releases
21days ago
MindMed Provides Corporate Update and 2023 Outlook MindMed Provides Corporate Update and 2023 Outlook Canada NewsWire NEW YORK, Jan. 9, 2023 - Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 - Company to initiate first clinical trial...
PR Newswire
2 months ago
MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference PR Newswire NEW YORK, Dec. 1, 2022 NEW YORK, Dec. 1, 2022...
CNW Group - News Releases
2 months ago
MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference Canada NewsWire NEW YORK, Dec. 1, 2022 NEW YORK, Dec. 1, 2022 /CNW...
PR Newswire
2 months ago
MindMed to Participate in the Jefferies London Healthcare Conference MindMed to Participate in the Jefferies London Healthcare Conference PR Newswire NEW YORK, Nov. 11, 2022 NEW YORK, Nov. 11, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the 'Company' or...
Frequently Asked Questions
Frequently Asked Questions
What is Mind Medicine Mindmed Inc share price today?
plus_minus_icon
Can Indians buy Mind Medicine Mindmed Inc shares?
plus_minus_icon
How can I buy Mind Medicine Mindmed Inc shares from India?
plus_minus_icon
Can Fractional shares of Mind Medicine Mindmed Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mind Medicine Mindmed Inc stocks?
plus_minus_icon
What is today’s traded volume of Mind Medicine Mindmed Inc?
plus_minus_icon
What is today’s market capitalisation of Mind Medicine Mindmed Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mind Medicine Mindmed Inc?
plus_minus_icon
What percentage is Mind Medicine Mindmed Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mind Medicine Mindmed Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.44
$0.03
(0.88%)
logo-mnmd
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PULMONX CORP
PULMONX CORP
$9.20
$0.25 (2.79 %)
Valneva SE
Valneva SE
$14.03
$0.29 (2.11 %)
Zomedica Corp
Zomedica Corp
$0.26
$0.01 (3.12 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$3.25
$-0.05 (-1.52 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
PULMONX CORP
PULMONX CORP
$9.20
$0.25 (2.79 %)
Valneva SE
Valneva SE
$14.03
$0.29 (2.11 %)
Zomedica Corp
Zomedica Corp
$0.26
$0.01 (3.12 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$3.25
$-0.05 (-1.52 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00